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Aims: To clarify the role of mesangial fibrinogen deposition in crescentic Henoch-Scho¨nlein nephritis
(HSN).
Methods: A retrospective analysis of 21 children with HSN treated with immunosuppressants. Serial renal
biopsies were performed before and after treatment. They were divided into two groups according to the
immunofluorescent course of fibrinogen deposition: group I (n = 9), no or decreased deposition; group II
(n = 12), persistent or increased deposition.
Results: There were no differences between the two groups in renal manifestations or laboratory and
histological findings at presentation. However, the activity index after immunosuppressive treatment was
significantly decreased in group I (mean, 7.9 (SEM, 0.7) v 2.9 (0.4); p = 0.008) and unchanged in group II
(mean, 6.8 (SEM, 0.3) v 6.0 (2.1)). The chronicity index was unchanged in group I, but increased in group
II (mean, 0.8 (SEM, 0.3) v 1.8 (0.3); p = 0.02). Univariate analysis revealed that the only factor
significantly related to persistent or increased fibrinogen deposition was age more than 9 years (p = 0.03).
Furthermore, the intensity of fibrinogen deposition at the second biopsy correlated positively with the age
at onset (R2 = 0.306; p = 0.009) and changes in the percentage of crescents (post-treatment crescents (%)
minus pretreatment crescents (%)) correlated positively with the intensity of fibrinogen deposition at the
second biopsy (R2 = 0.193; p = 0.046).
Conclusions: This study indicates that fibrinogen deposition has an important role to play in renal injury of
crescentic HSN and reflects persistent severe histological activity.
H
enoch-Scho¨nlein purpura is a vasculitis with IgA
dominant immune deposits that predominantly affect
the skin, gastrointestinal tract, joints, and kidneys.
Although Henoch-Scho¨nlein purpura is usually acute and self
limited, the longterm prognosis is dependent on the severity
of renal involvement (Henoch-Scho¨nlein nephritis; HSN).1
Patients with nephrotic range proteinuria, nephrotic/nephri-
tic syndrome at onset, and a high percentage of crescents
show a progressive course.2 3 In specialised nephrology
centres, an estimated 10% or more of children with HSN
progress to end stage renal failure.2–4
‘‘It was suggested that fibrinolytic treatment should be
dependent on the characteristics of the individual patient
because crescents associated with Henoch-Scho¨nlein
nephritis are not always fibrinogen dependent’’
Previous studies reported that several immunosuppressive
agents have a beneficial effect on HSN.4–6 Recently, Watanabe
et al and Kawasaki et al described the efficacy of urokinase in
the treatment of severe HSN, and suggested that fibrinolytic
treatment could help relieve an intraglomerular hypercoagul-
able state related to renal injury and preserve renal
function in patients with severe crescentic HSN.7–9 However,
it was suggested that fibrinolytic treatment should be
dependent on the characteristics of the individual patient
because crescents associated with HSN are not always
fibrinogen dependent.
Therefore, we compared the clinical and histological
findings between patients with no or decreased fibrinogen
deposits and those with persistent or increased deposits by
serial renal biopsy to identify the role of fibrinogen deposition
in crescentic HSN.
PATIENTS AND METHODS
Patients
From the years 1990 to 2002 we analysed the serial renal
biopsy specimens of 21 (15 male and six female) children
with at least grade IIIa HSN (see later), aged 3.6–15.5 years.
HSN was diagnosed when haematuria and/or proteinuria
were associated with a characteristic purpuric eruption and/
or abdominal or joint pain, and the presence of glomerular
IgA deposits was the main diagnostic criterion. Patients with
IgA nephropathy without a classic Henoch-Scho¨nlein pur-
pura rash were excluded. All patients were treated with
prednisolone and immunosuppressants (azathioprine or
cyclosporine). They were divided into two groups according
to the immunofluorescent (IF) course of fibrinogen deposi-
tion: group I (n = 9), no deposition or decreased deposition;
group II (n = 12), persistent or increased deposition. The
mean duration of follow up was 5.8 years (range, 1–12).
The clinical outcome at the end of immunosuppressive
treatment or at the latest observation was graded as follows3:
(A) normal urine and renal function; (B) microscopic
haematuria or proteinuria less than 40 mg/m2/hour; (C)
active renal disease with proteinuria of 40 mg/m2/hour and a
glomerular filtration rate of 60 ml/min/1.73 m2 or greater;
(D) renal insufficiency. Our study was approved by the
institutional review board and the research ethics committee
of Yonsei Severance Hospital, Korea.
Histopathology
All patients underwent percutaneous renal biopsy before and
after immunosuppressive treatment. The mean interval
between biopsies was 11.2 months (range, 8–14), and was
Abbreviations: IF, immunofluorescent; ISKDC, International Study of
Kidney Disease in Children; HSN, Henoch-Scho¨nlein nephritis
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similar between the two groups. The glomerular changes
were graded according to the classification of the
International Study of Kidney Disease in Children (ISKDC)
(grade I, minimal alterations; grade II, mesangial prolifera-
tion; grade IIIa/b, focal/diffuse proliferation or sclerosis with
, 50% crescents; grade IVa/b, focal/diffuse proliferation or
sclerosis with 50–75% crescents; grade Va/b, focal/diffuse
proliferation or sclerosis with . 75% crescents; grade VI,
membranoproliferative glomerulonephritis).2 Renal biopsy
specimens were also scored semiquantitatively using the
modified scoring system of Foster et al.5 Acute changes
included mesangial hypercellularity (0–3), mesangial matrix
increase (0–3), endothelial swelling (0–2), interstitial mono-
nuclear infiltrate (0–2), interstitial oedema (0–2), tubular
damage (0–2), cellular crescents (0–3), basement membrane
adhesion to Bowman’s capsule (0–3), glomerular neutrophils
(0–3), and fibrinoid necrosis (0–3). Chronic renal injury was
estimated by interstitial fibrosis and tubular atrophy (0–2),
fibrous crescents (0–3), global sclerosis (0–3), and vascular
hyalinosis and intimal hyperplasia (0–1). The sum of these
numbers comprised the activity index and the chronicity
index, respectively. The scores from four factors (interstitial
mononuclear infiltrate, interstitial oedema, tubular damage,
and interstitial fibrosis and tubular atrophy) were combined
into the tubulointerstitial scores.
For the IF microscopic examination, a portion of the fresh
renal tissuewas frozenandexposed to fluorescein isothiocyanate
conjugated antihuman IgG, IgA, IgM, C3, and fibrinogen. The
overall intensity of IF was also scored semiquantitatively, as
follows: 0, negative; 0.5, trace; 1,mild;2,moderate; and3, severe.
Statistical analysis
Statistical analysis was performed using SPSS version 11.0
(SPSS Inc, Chicago, Illinois, USA). Continuous variables were
expressed as mean values (SEM). Variables were compared
using the Mann-Whitney test and Fisher’s exact test.
Differences between biopsy findings before and after treat-
ment were assessed by the Wilcoxon signed rank test.
Correlation between two variables was assessed by
Spearman’s rank correlation test; p , 0.05 was considered
significant.
RESULTS
Patients’ characteristics
There were no differences between the two groups with
regard to sex, hypertension, macroscopic haematuria,
nephrotic/nephritic syndrome, or treatment. The duration of
follow up was similar for the two groups. The age at onset
had borderline significance (p = 0.058), but data analysis at
various cutoff values of age revealed that an age more than 9
years was a significant factor related to persistent or
increased fibrinogen deposition (p = 0.03).
Twenty of the 21 patients showed normal urinalysis or
minor urinary abnormalities at the latest observation.
Although one patient in group II progressed to chronic renal
insufficiency, there was no significant difference between the
two groups in the clinical outcome at the end of immuno-
suppressive treatment or at the latest observation (table 1).
Laboratory findings
There were no significant differences between the two groups
in urinary protein excretion, serum albumin, creatinine, and
creatinine clearance at the first and second biopsy. In both
groups, urinary protein excretion was decreased significantly
and serum albumin was increased after immunosuppressive
treatment, whereas serum creatinine and creatinine clear-
ance did not change (table 2).
Histopathological findings
Table 3 shows the light microscopic findings of the 21
patients. At the first renal biopsy, the histological grade of the
ISKDC and the activity indices did not differ between the two
groups. The percentage of crescents in group I was higher
than that in group II (p = 0.025). The second biopsy from
patients in group I showed improvement (n = 9) of the
histological grade of the ISKDC (p = 0.004) and a decrease
in the activity index (p = 0.008), whereas the second biopsy
from patients in group II showed improvement (n = 2), no
changes (n = 7), or progression (n = 3) of the grade of the
ISKDC and persistent increase of the activity index. The
percentage of crescents at the second biopsy was decreased in
group I, but unchanged in group II. There were no differences
between the two groups with regard to the chronicity index
and tubulointerstitial scores of the first renal biopsy. At the
second biopsy, however, the chronicity index (p = 0.012)
and tubulointerstitial scores (p = 0.009) in group II were
significantly higher than those in group I.
Table 4 shows the IF results. We used the IF course
of mesangial fibrinogen deposition as the criterion for
Table 1 Clinical characteristics of the two groups
Group I (n = 9) Group II (n = 12)
Age at onset (years)* 7.4 (1.3) 10.2 (0.9)
Age .9 years 2 9
Sex (male:female) 6:3 9:3
Follow up (years) 5.2 (0.8) 6.3 (0.9)
Initial renal manifestations
Macroscopic haematuria 2 5
Hypertension 2 3
Mild proteinuria 1 2
Nephrotic range proteinuria 6 7
Nephrotic syndrome 2 3
Acute nephritic pictures 1 1
Treatment
Azathioprine 4 5
Cyclosporine 5 7
Clinical outcome (A/B/C/D)
At the end of treatment 4/5/0/0 5/5/2/0
At the latest observation 7/2/0/0 8/3/0/1
*p =0.058 and p =0.03 between the two groups.
Table 2 Laboratory findings in the two groups
Variables
First biopsy Second biopsy
Group I (n = 9) Group II (n = 12) Group I (n = 9) Group II (n = 12)
Proteinuria (g/m2/day) 4.6 (1.4) 5.4 (1.3) 0.1 (0.03)* 0.5 (0.1)*
Albumin (g/l) 30 (2.0) 32 (3.0) 44 (1.0)* 42 (1.0)*
Creatinine (mg/l) 6.0 (1.0) 7.0 (1.0) 5.0 (1.0) 7.0 (1.0)
CCr (ml/min/1.73 m2) 82.0 (6.1) 109.0 (10.2) 117.0 (22.1) 104.9 (7.7)
No differences between the two groups.
Values are mean (SEM).
*p,0.01 compared with the first biopsy.
CCr, creatinine clearance.
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separating groups I and II. At the first biopsy, the amount of
IgG, IgA, IgM, C3, and fibrinogen in the deposits did not
differ between the two groups. At the second biopsy,
however, the degree of mesangial fibrinogen deposition in
group I was decreased compared with the first biopsy (mean,
1.4 (SEM, 0.5) v 0.4 (0.2); p = 0.031), whereas it was
slightly increased in group II (mean, 0.8 (SEM, 0.2) v 1.1
(0.1); p = 0.125), although it was not significantly different.
Thus, mesangial fibrinogen deposits at the second biopsy in
group II were significantly higher than those in group I
(mean, 0.4 (SD, 0.2) v 1.1 (0.1); p = 0.012). Other deposits
did not differ between the two groups.
Correlation of fibrinogen deposition with the age at
onset and changes in the percentage of crescents
The degree of mesangial fibrinogen deposition at the second
biopsy correlated positively with the age at onset (fibrinogen
deposition = 0.0886age at onset; R2 = 0.306; p = 0.009).
Changes in the percentage of crescents (post-treatment
crescents (%) 2 pretreatment crescents (%); Dcrescents)
correlated positively with the intensity of mesangial fibrino-
gen deposits at the second biopsy (Dcrescents = 12.368 6
fibrinogen deposition – 17.623; R2 = 0.193; p = 0.046)
(fig 1).
DISCUSSION
Irrespective of aetiology, crescentic glomerulonephritis is
indicative of severe glomerular injury, and the proportion of
crescents is an important factor in determining prognosis.10
Crescent formation is associated with various factors, such as
the accumulation of T cells, macrophages, tissue factor,
components of delayed-type hypersensitivity, and fibrin
deposition.11 Among these factors, several human and
experimental studies have shown that glomerular fibrin
deposition plays an important role in the mechanism of
crescent formation.12 13 In experimental models, defibrination
decreased the number of crescents and the severity of renal
insufficiency.14 15 Recent studies, using genetic engineering,
have shown that crescentic glomerulonephritis is reduced in
mice that are genetically deficient in fibrinogen and increased
in those overexpressing the plasminogen activator inhibitor-1
gene.16 17
However, the mechanisms responsible for fibrin deposition
and crescent formation and the precise role of coagulation in
the pathogenesis of IgA nephropathy or HSN are still poorly
understood.18–20 It was suggested that the activation of
intraglomerular coagulation is one of the exacerbative factors
in IgA nephropathy and HSN.18 19 Miura et al reported that
glomerular injury, such as glomerular adhesion to Bowman’s
capsule and crescents, was seen predominantly in glomeruli
with a2-plasmin inhibitor and/or fibrinogen deposits in
patients with IgA nephropathy, and suggested that the
deposition of a2-plasmin inhibitor in vivo might lead to the
accumulation of glomerular fibrinogen deposits.18 Ono et al
reported that crosslinked fibrin in the glomeruli is associated
with relatively low intraglomerular plasmin activity and
intraglomerular coagulation, both in IgA nephropathy and in
HSN.19
Therefore, it was thought that fibrinolytic treatment might
help to preserve renal function in patients with IgA
nephropathy or HSN. Several reports from the 1980s showed
the beneficial effects of urokinase on severe IgA nephro-
pathy,21 and Watanabe et al first used this treatment in a
small number of patients with severe HSN.7 Recently,
Kawasaki et al reported the efficacy of urokinase combined
with a methylprednisolone pulse or cyclophosphamide in
patients with severe crescentic HSN,8 9 because glomerular
fibrinogen deposits are seen much more frequently in HSN
than in IgA nephropathy.22
We postulated that there would be differences in crescent
formation and glomerular fibrinogen deposition among
patients with HSN, and that fibrinolytic treatment should
be tailored to the characteristics of the individual patient
because HSN is a heterogeneous disease with several
histopathological presentations, and crescents associated
with HSN are not always fibrinogen dependent. In our study,
Table 3 Light microscopic findings in the two groups
Variables
First biopsy
p Value
Second biopsy
p ValueGroup I (n = 9) Group II (n = 12) Group I (n = 9) Group II (n = 12)
ISKDC NS 0.015
I 0 0 2 0
II 0 0 6 2
IIIa 6 9 1 6
IIIb 2 3 0 3
IVb 1 0 0 1
AI 7.9 (0.7) 6.8 (0.3) NS 2.9 (0.4)* 6.0 (2.1) 0.001
CI 0.4 (0.2) 0.8 (0.3) NS 0.4 (0.2) 1.8 (0.3) 0.012
TI score 1.0 (0.5) 1.7 (0.4) NS 0.4 (0.2) 3.1 (0.8) 0.009
Crescents (%) 21.9 (5.8) 12.4 (3.3) NS 1.4 (1.4)* 13.9 (5.0) 0.019
Values (except for ISKDC results) are mean (SEM).
*p,0.01 and p,0.05 when compared with the first biopsy.
AI, activity index; CI, chronicity index; ISKDC, International Study of Kidney Disease in Children; NS, not significant; TI, tubulointerstitial.
Table 4 Immunofluorescent findings in the two groups
Variable
First biopsy
p Value
Second biopsy
p ValueGroup I Group II Group I Group II
IgG 0.4 (0.2) 0.3 (0.2) NS 0.2 (0.1) 0.1 (0.1) NS
IgA 1.9 (0.4) 1.9 (0.2) NS 1.1 (0.2)* 1.6 (0.2) NS
IgM 0.3 (0.2) 0.3 (0.1) NS 0.3 (0.1) 0.2 (0.1) NS
C3 0.6 (0.3) 0.5 (0.1) NS 0.3 (0.2) 0.8 (0.3) NS
Fibrinogen 1.4 (0.5) 0.8 (0.2) NS 0.4 (0.2)* 1.1 (0.1) 0.012
Values are mean (SEM).
*p,0.05 when compared with the first biopsy.
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we classified the patients with HSN and crescentic change
into two groups. This was not based on initial biopsy findings
but on the subsequent course of the mesangial fibrinogen
deposits. Although other authors had treated patients
according to the fibrinogen deposits at the first biopsy, we
found heterogeneous serial changes of fibrinogen deposition
between the first and second biopsy: two patients had no
fibrinogen deposits throughout the course of the disease and
seven showed a reduction or disappearance of crescents and
fibrinogen deposits with only immunosuppressants in group
I, whereas three patients who had shown no fibrinogen
deposits at the first biopsy developed new fibrinogen deposits
at the second biopsy, and nine had persistent or increased
fibrinogen deposits despite immunosuppressants in group II.
Although clinical improvement was achieved even in patients
with persistent or increased fibrinogen deposits, severe
histological abnormalities persisted without regression in 10
of the 12 group II patients, suggesting that persistent or
increased deposition of intraglomerular fibrinogen plays an
important role in the pathogenesis of crescentic HSN.
Therefore, we were interested in discriminating between
these two groups, and compared the clinical and histopatho-
logical findings at the time of the first biopsy. We found that
an age greater than 9 years at onset was the only factor that
was significantly related to persistent or increased fibrinogen
deposition, and that age at onset was positively correlated
with the intensity of fibrinogen deposition at the second
biopsy. Although Tanaka et al reported that the age at onset in
childhood IgA nephropathy has an effect on the histological
changes seen after treatment with prednisolone, with
children older than 10 showing more severe histological
findings at the second biopsy,23 there has been no study
describing the effect of age on histological responses to
immunosuppressive treatment in severe HSN. We found that
children with HSN greater than 9 years of age at onset had
more severe fibrinogen deposits during the course of the
disease and a worse response to immunosuppressants than
those less than 9 years of age, suggesting that the age at onset
influences the subsequent course of fibrinogen deposition
and outcome. In addition, the intensity of fibrinogen
deposition at the second biopsy positively correlated with
the changes in the number of crescents, indicating that
fibrinogen deposition is an important factor in the pathogen-
esis of crescentic HSN. Fibrinolytic treatment can help to
ameliorate the progression of renal injury and histopatholo-
gical changes related to severe fibrinogen deposition in older
children with crescentic HSN, although fibrinolytic treatment
was not used in our study.
‘‘Further studies should be undertaken to investigate
whether fibrinogen deposition influences the clinical out-
come of Henoch-Scho¨nlein nephritis and can be used as a
prognostic factor’’
However, there are some limitations to our study. (1) There
is no clear evidence that the deposition of fibrinogen alone is
responsible for crescent formation in HSN. (2) We could
show no differences between the two groups in clinical
outcome at the end of the follow up period, including
proteinuria, creatinine clearance, and progression to chronic
renal failure, and the range of intensity of fibrinogen
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Figure 1 Correlations between the intensity of fibrinogen deposition at
the second biopsy, age at onset, and change in the % of crescents. (A)
The intensity of fibrinogen deposition at the second biopsy correlated
positively with the age at onset. (B) Change in the % of crescents
correlated positively with intensity of fibrinogen deposition at the second
biopsy.
Take home messages
N We compared two groups of children with Henoch-
Scho¨nlein nephritis (HSN) treated with immunosup-
pressants: those with no or decreased deposition of
fibrinogen (group I) and those with persistent or
increased deposition (group II) after treatment
N The post-treatment activity index was significantly
decreased in group I and unchanged in group II
N Age greater than 9 years at presentation was the only
factor significantly related to persistent or increased
fibrinogen deposition and the intensity of fibrinogen
deposition at the second biopsy correlated positively
with the age at onset and changes in the percentage of
crescents correlated positively with the intensity of
fibrinogen deposition at the second biopsy
N Thus, fibrinogen deposition plays an important role in
renal injury in crescentic HSN and reflects persistent
severe histological activity
1150 Shin, Park, Shin, et al
www.jclinpath.com
deposition was relatively limited, probably as a result of the
aggressive immunosuppressive treatment. Therefore, it appears
that the amount of fibrinogen deposition has no effect on
clinical outcome in immunosuppressant treated patients, but is
associated with persistently increased histological activity. (3)
Considering the spontaneous improvement of renal symptoms
in most patients with Henoch-Scho¨nlein purpura and a
possible risk of bleeding, only a small number of patients
would require fibrinolytic treatment.
Nevertheless, our study suggests that persistent or
increased fibrinogen deposition during the course of the
disease is closely associated with severe renal injury and
persistent histological activity in children with crescentic
HSN. Fibrinolytic treatment should be added according to the
characteristics of the individual patient and restricted to older
children with the risk of severe fibrinogen deposition. Further
studies should be undertaken to investigate whether fibrino-
gen deposition influences the clinical outcome of HSN and
can be used as a prognostic factor.
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